Evidence map›Paper›PMID 35430668›Full record

ArticleAnnals of surgical oncology2022

SUCCOR Risk: Design and Validation of a Recurrence Prediction Index for Early-Stage Cervical Cancer.

Nabil Manzour, Luis Chiva, Enrique Chacón, Nerea Martin-Calvo, Felix Boria, José A Minguez, Juan L Alcazar, SUCCOR Study Group

Open access · hybridAbstract readValidation Study
In one paragraph

Article in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Nabil ManzourDepartment of Gynecology, Clinica Universidad de Navarra, Pamplona, Spain.ORCID http://orcid.org/0000-0002-4604-6042
Luis ChivaDepartment of Gynecology, Clinica Universidad de Navarra, Pamplona, Spain. lchiva@unav.es.ORCID http://orcid.org/0000-0002-1908-3251
Enrique ChacónDepartment of Gynecology, Clinica Universidad de Navarra, Pamplona, Spain.ORCID http://orcid.org/0000-0001-8659-8602
Nerea Martin-CalvoDepartment of Preventive Medicine and Public Health, Universidad de Navarra, Pamplona, Spain.ORCID http://orcid.org/0000-0001-7549-1455
Felix BoriaDepartment of Gynecology, Clínica Universidad de Navarra, Madrid, Spain.ORCID http://orcid.org/0000-0002-4761-6190
José A MinguezDepartment of Gynecology, Clinica Universidad de Navarra, Pamplona, Spain.ORCID http://orcid.org/0000-0003-3635-8920
Juan L AlcazarDepartment of Gynecology, Clinica Universidad de Navarra, Pamplona, Spain.ORCID http://orcid.org/0000-0002-9700-0853
SUCCOR Study Group
Clinica Universidad de Navarra · ESUniversidad de Navarra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveBased on the SUCCOR study database, our primary objective was to identify the independent clinical pathological variables associated with the risk of relapse in patients with stage IB1 cervical cancer who underwent a radical hysterectomy. Our secondary goal was to design and validate a risk predictive index (RPI) for classifying patients depending on the risk of recurrence.

methodsOverall, 1116 women were included from January 2013 to December 2014. We randomly divided our sample into two cohorts: discovery and validation cohorts. The test group was used to identify the independent variables associated with relapse, and with these variables, we designed our RPI. The index was applied to calculate a relapse risk score for each participant in the validation group.

resultsA previous cone biopsy was the most significant independent variable that lowered the rate of relapse (odds ratio [OR] 0.31, 95% confidence interval [CI] 0.17-0.60). Additionally, patients with a tumor diameter >2 cm on preoperative imaging assessment (OR 2.15, 95% CI 1.33-3.5) and operated by the minimally invasive approach (OR 1.61, 95% CI 1.00-2.57) were more likely to have a recurrence. Based on these findings, patients in the validation cohort were classified according to the RPI of low, medium, or high risk of relapse, with rates of 3.4%, 9.8%, and 21.3% observed in each group, respectively. With a median follow-up of 58 months, the 5-year disease-free survival rates were 97.2% for the low-risk group, 88.0% for the medium-risk group, and 80.5% for the high-risk group (p < 0.001).

conclusionPrevious conization to radical hysterectomy was the most powerful protective variable of relapse. Our risk predictor index was validated to identify patients at risk of recurrence.

Indexed as

Neoplasm Recurrence, LocalNeoplasm StagingUterine Cervical NeoplasmsFemaleHumansHysterectomyPrognosisRecurrenceRetrospective StudiesRisk Assessment

Identifiers

PMID35430668
PMCPMC9246807
OpenAlexW4224137500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.